Product

The GlydeTM CGM is a miniature, long-lived, fully implantable continuous glucose monitoring device (CGM), with no need for wearables or skin-attached elements, delivering a hassle-free CGM experience and eliminating the daily hassle of taking glucose measurements.
The implant transmits accurate information on blood glucose levels direct to mobile, provides reliable alerts, is invisible to the eye, and can operate for years without replacement.

Glucose sensing in the Glyde CGM is done using an optical fluorescence measurement. A proprietary fluorescent protein (‘biosensor’) inside the Glyde implant changes its fluorescence properties upon selectively binding to glucose. Optical measurement and accurate algorithmic analysis is performed by the implant, quantifying fluorescence levels and enabling accurate blood glucose readings.

Current implantable sensors struggle to maintain long term functionality, as active materials in the implant decay over time. GluSense’s breakthrough technology allows for constant replenishing of the active biosensor, using a miniscule amount of modified human retina cells, safely encapsulated inside the device, allowing for theoretically infinite device longevity and eliminating the need for yearly re-implantations.  

GluSense patented, innovative technology is unique in its potential for truly long term operation, while maintaining a minimal form factor.


Technology

Biosensor

Glucose detection is performed using a proprietary fluorescent Biosensor protein having two fluorophore groups and a glucose binding domain. Utilizing the Fluorescent Resonant Energy Transfer (FRET) effect, the biosensor changes its fluorescent emission upon selectively binding to a glucose molecule.  As the binding is reversible, the percentage of biosensor molecules which are found at the bound state at a given moment is determined by the glucose concentration in the medium.   Utilizing the FRET effect, two fluorescent signals are detected in every measurement event, where one signal is glucose-sensitive and the other is glucose-insensitive.  By taking the ratio between the two fluorescent signals a robust measurement is obtained, which is insensitive to changes in biosensor concentration or exact measurement conditions.  The patented Biosensor has been optimized by GluSense for best response in the full physiological range of glucose values with special emphasis on low glucose values, which are critical in order to prevent hypoglycemia.

Cells

Maintaining sensor functionality for the long term in the human body is challenging using current sensing technologies, as the active material, enzyme or fluorescent molecule, decays in the body over just a few weeks. GluSense’s breakthrough technology utilizes modified human retina cells to continuously replenish the Biosensor and assure fresh biosensor is always available, without the need to grow the size of the implant.  A minuscule amount of cells are encapsulated inside a compartment of the implant, effectively separated from the body by a selective membrane which restricts the exit of the cells, yet allows glucose and oxygen to diffuse in and out of the implant.